Kymera Therapeutics (NASDAQ:KYMR) Sets New 1-Year High at $53.00

Kymera Therapeutics, Inc. (NASDAQ:KYMR) reached a new 52-week high on Wednesday . The company traded as high as $53.00 and last traded at $52.24, with a volume of 62422 shares trading hands. The stock had previously closed at $52.40.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Morgan Stanley lifted their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Wells Fargo & Company upped their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partnrs raised shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.67.

Kymera Therapeutics Price Performance

The company has a market cap of $3.24 billion, a price-to-earnings ratio of -20.91 and a beta of 2.22. The business’s fifty day moving average price is $45.46 and its 200 day moving average price is $39.16.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million for the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business’s quarterly revenue was up 55.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.67) EPS. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.87 EPS for the current year.

Insider Activity at Kymera Therapeutics

In other news, Director Bruce Booth sold 453,960 shares of the stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares in the company, valued at $27,635,229.66. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jared Gollob sold 23,145 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total value of $1,060,272.45. Following the sale, the insider now owns 95,470 shares in the company, valued at approximately $4,373,480.70. The disclosure for this sale can be found here. Insiders have sold 495,605 shares of company stock worth $19,303,364 over the last ninety days. Insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. boosted its stake in Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after acquiring an additional 295 shares in the last quarter. Comerica Bank grew its stake in shares of Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the period. Keudell Morrison Wealth Management grew its stake in shares of Kymera Therapeutics by 7.2% in the 2nd quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after buying an additional 480 shares during the period. Congress Asset Management Co. MA increased its position in Kymera Therapeutics by 1.2% in the 1st quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after buying an additional 533 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in Kymera Therapeutics by 4.7% during the 1st quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock worth $486,000 after buying an additional 547 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.